37 results about "Iodide sodium" patented technology

The invention can be summarized as follows. According to the present invention there is provided an attenuated, tumour-targeting bacterium comprising a heterologous nucleotide sequence encoding a protein permitting the accumulation of a radionuclide within the bacterium. The heterologous nucleotide sequence may encode a sodium iodide symporter protein. The invention also relates to the use of such bacteria and methods of treating diseases using the bacteria of the present invention.

The invention provides a novel route cefprozil compound, which simplifies the processes of 7-phenacetylamino-3-chloromethyl cephalosporanic acid anisyl acetate and triphenylphosphine phyllocaline Benedict's reagents, and activating reagents such as sodium iodide and the like do not need to be added, so the post treatment is simple and convenient, the production amplification can be realized more easily, and at the same time, para hydroxybenzene glycine is adopted to react with 2, 4, 6-trichlorophenol to generate a novel intermediate product of para hydroxybenzene glycine 2, 4, 6- phenyl estertrichlorine. The stability and the activity of the compound are mild, by-products produced in the reaction are fewer, the reaction yield is improved, and in addition, the obtained products have high purity and low isomeride content.

This document provides methods and materials involved in radiotracer imaging using NIS polypeptides. For example, methods and materials for performing imaging techniques that increase the detection sensitivity and resolution of radiotracers localized by NIS reporter gene expression and / or decrease background signals that can be attributed to endogenously expressed NIS polypeptides are provided.

The invention discloses a triptolide prodrug as well as a preparation method and medical application thereof. Belongs to the field of pharmaceutical chemistry. The preparation method comprises the following steps: 1, reacting triptolide with acyl chloride under the action of DMAP to generate an intermediate II; 2, reacting the intermediate II with a carboxylic acid compound under the action of sodium iodide and potassium carbonate to generate a compound III; and 3, salifying the compound III and acid to obtain the target compound I. The derivative has better water solubility and pharmacokinetic properties, and compared with Minnelide, the derivative has a faster conversion speed in an in-vivo blood environment and a more efficient synthesis method, and has a better treatment effect on malignant tumors, inflammatory diseases, autoimmune diseases and the like; in addition; due to good water solubility, the compound is effective in oral administration and can be prepared into an injection for use.

The invention discloses a preparation method of 1-bromoalkyne and 1-iodoalkyne. The preparation method comprises the following steps that terminal alkyne is adopted as a raw material, a chloramine salt and an iodine salt or a bromine salt is adopted as a halogenation system, and reaction is carried out in a solvent to synthesize a series of 1-bromoalkyne and 1-iodoalkyne type compounds. In the formula shown in the description, R in terminal alkyne is selected from chain-like alkyne, ring-shaped alkyne, olefin, ester group, cyanogroup, substituted phenyl group and heterocyclic arene; the chloramine salt is selected from one of chloramine B, chloramine T or o-chloramine T; the iodine salt is selected from one of sodium iodide, potassium iodide, ammonium iodide, lithium iodide or tetrabutylammonium iodide; the bromine salt is selected from one of sodium bromide, potassium bromide, lithium bromide, magnesium bromide, ammonium bromide or tetrabutylammonium bromide; the solvent is selected from one or is mixed by two of water, benzene, methylbenzene, 1, 4-dioxane, ethyl acetate, dimethyl sulfoxide, methanol, tetrahydrofuran, alcohol, isopropyl alcohol, N, N-dimethyl formamide, n-pentane,dichloromethane, petroleum ether, methyl tert-butyl ether, chloroform, n-hexane, carbon tetrachloride, n-butyl alcohol, 1,2-dichloroethane or acetonitrile. The preparation method disclosed by the invention has the beneficial effect that the application is wide.

A preparation method of ticagrelor key intermediate iodide, comprising the following steps: (1) synthesis of intermediate 1, (3) synthesis of key intermediate iodide, the synthesis of described intermediate 1 is based on D- Ribose is used as a raw material, methanol and acetone are used as a solvent, thionyl chloride is added as a catalyst, and the solvent is concentrated and removed after the reaction to obtain the intermediate 1; the synthesis of the key intermediate iodide uses acetonitrile as a solvent, and the Intermediate 1. Sodium iodide is added to the reaction system, trimethylchlorosilane is added dropwise, a small amount of water is added after the reaction is completed to quench the reaction, acetonitrile is evaporated, solvent extraction, and concentration to obtain the key intermediate iodide. In the preparation method of ticagrelor key intermediate iodide of the present invention, in the synthesis process of intermediate 1, thionyl chloride is used instead of hydrochloric acid as a catalyst, the reaction conversion rate is greatly improved, and then trimethylchlorosilane is used as a catalyst. / Sodium iodide is used as an iodinating agent, the reaction conditions are mild, the post-treatment is simple and the conversion rate is high.

The invention discloses a comprehensive efficient centrifugal machine for sodium iodide production. The comprehensive efficient centrifugal machine for sodium iodide production comprises a tank body, a tank cover and a fine-hole filter screen, the bottom of the front end of the tank body communicates with a discharge valve which is obliquely distributed, the tank cover is installed at the top of the tank body, a driving motor which is vertically distributed is installed at the bottom of the tank body, a transmission shaft is in transmission connection with the top of the driving motor and located on the inner side of the tank body, and the fine-hole filter screen is fixedly connected to the middle of the transmission shaft. According to the comprehensive efficient centrifugal machine for sodium iodide production, firstly, a comprehensive centrifugal structure is adopted, a solution can be subjected to comprehensive drainage and centrifugal separation operation, the solid-liquid layering rate is increased, and therefore the solid-liquid centrifugal separation efficiency of the solution is improved, secondly, a lifting and filtering type slag discharging structure is adopted, solid impurities obtained after centrifugal separation can be rapidly filtered out of the solution, conveyed and collected in a centralized mode, and the participation of a procedure of manually separating and filtering solid impurities is reduced, so that the production efficiency of the sodium iodide is improved.

The present invention relates to the field of pharmacy, and specifically provides an improved method for preparing salsacillin hydroiodide, the method comprising 1) dissolving salsacillin citrate in water, then adding sodium iodide or potassium iodide solution to react, and growing crystals , filtered, washed and dried to obtain sacillin hydroiodide. The method of the invention has the advantages of high yield, easy operation and low toxicity, mild reaction conditions, is beneficial to product purification, intermediate storage and impurity control, and can obtain a sacillin hydroiodide product with good stability.

The invention discloses a preparation method of a compound 5-amino-2-azaspiro [3.4] octane-2-carboxylic acid tert-butyl ester. The preparation method comprises the following steps: 1. dissolving a compound 1 and a compound 2 in 2-methyl tetrahydrofuran, dropwisely adding lithium bis (trimethylsilyl) amide, and reacting to obtain a compound 3; 2, dissolving the compound 3 into acetone, and reactingwith sodium iodide to obtain a compound 4; 3, dissolving the compound 4 in 2-methyl tetrahydrofuran, dropwise adding n-butyllithium, and reacting to obtain a compound 5; 4, adding the compound 5 andamine into 1, 2-dichloroethane, then adding acetic acid and a reducing agent, and reacting to obtain a compound 6; and 5, dissolving the compound 6 in ethanol, adding a catalyst, and reacting in hydrogen to obtain a compound 7. The novel spiro compound structure is designed autonomously, a synthetic route is developed, and a synthetic method suitable for industrial production is found through continuous optimization.

The present disclosure relates to a sodium iodide symporter (NIS)-repressor binding site (NRBS) consisting of a DNA molecule spanning from −645 to −605 nucleotides (SEQ ID NO:4) or from −648 to −620 nucleotides (SEQ ID NO:5) upstream from the translation start site of human NIS gene. The disclosure further relates to a method of restoring iodide transport to a human thyroid carcinoma cell, including: the steps of: i) contacting the cell expressing and forming a NIS repressor protein complex capable of binding to the NRBS of the disclosure with a modulator of said complex, and ii) administering to the cell radiolabeled iodide.

A modified sodium iodide symporter (NIS) protein is provided. The modified NIS protein comprises an amino acid sequence of SEQ ID NO.1 with the proviso that at least one amino acid residue within SEQ ID NO. 1 is changed. The modified NIS protein has an enhanced transport function, and the expression of the modified NIS protein in the cells results in higher intracellular levels of a substrate of a NIS protein than does the expression of the same amount of a wild-type NIS protein.

The present invention relates to a metal halide lamp pill. The metal halide lamp pill contains iodides of scandium, sodium, thorium, thallium and indium, and it also contains iodides of lithium and dysprosium. The weight ratio of each component is: scandium iodide 70-90 10-20 parts of sodium iodide, 0.03-0.1 parts of thorium iodide, 0.05-0.15 parts of thallium iodide, 0.01-0.04 parts of indium iodide, 0.05-0.15 parts of lithium iodide, and 0.05-0.10 parts of dysprosium iodide. The invention changes the spectral components and proportions in the plasma discharge, increases the proportion of visible light, increases the tube wall load of the arc tube, and increases the luminous flux per unit power. The metal halide lamp prepared by using the metal halide lamp pellets of the invention has a quality exceeding the national standard, has a high light efficiency of more than 120Lm / w, and has a service life of more than 12000 hours, thereby achieving the purpose of energy saving and environmental protection.

The invention discloses a luminous pill of a metal halide white lamp, which contains sodium iodide, thallium iodide, indium iodide, iridium iodide and americium iodide. Compared with the prior art, the prepared metal halide white lamp is characterized by good color rendering, the color rendering index being larger than 80, and good photochromic consistency.

The invention provides a novel synthesis method of a Selinexor active pharmaceutical ingredient. The method comprises the following steps: mixing a compound 6, dichloromethane and ethyl acetate, adding a compound 4, T3P and DIPEA (diisopropylethylamine) at low temperature, reacting, adding water and ethyl acetate, skimming, and drying up the organic phase by distillation to obtain a compound 7 crude product; mixing the compound 7, glacial acetic acid and sodium iodide, heating and reacting; after the reaction finishes, cooling, adding water and dichloromethane, standing to stratify, washing the organic phase, drying, and distilling to obtain a compound 8; mixing the compound 1, DBACO and DMF (N,N-dimethylformamide), dropwisely adding a compound 8 DMF solution, and reacting; and after the reaction finishes, adding water and ethyl acetate, drying up the organic phase by distillation, and recrystallizing to obtain the compound 5. The synthesis method solves the problem that the traditional synthesis technique can easily generate trans impurities, reduces the synthesis steps, enhances the yield, and provides a new technique for synthesizing the Selinexor active pharmaceutical ingredient.